175 related articles for article (PubMed ID: 31215774)
1. Recommendations for the Design of Clinical Drug-Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically-Based Pharmacokinetic Model.
Chen Y; Cabalu TD; Callegari E; Einolf H; Liu L; Parrott N; Peters SA; Schuck E; Sharma P; Tracey H; Upreti VV; Zheng M; Zhu AZX; Hall SD
CPT Pharmacometrics Syst Pharmacol; 2019 Sep; 8(9):685-695. PubMed ID: 31215774
[TBL] [Abstract][Full Text] [Related]
2. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
3. Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction.
Chen Y; Ma F; Lu T; Budha N; Jin JY; Kenny JR; Wong H; Hop CE; Mao J
Clin Pharmacokinet; 2016 Jun; 55(6):735-49. PubMed ID: 26692192
[TBL] [Abstract][Full Text] [Related]
4. Semi-mechanistic population pharmacokinetic drug-drug interaction modelling of a long half-life substrate and itraconazole.
Lehr T; Staab A; Trommeshauser D; Schaefer HG; Kloft C
Clin Pharmacokinet; 2010; 49(1):53-66. PubMed ID: 20000889
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.
Budha NR; Ji T; Musib L; Eppler S; Dresser M; Chen Y; Jin JY
Clin Pharmacokinet; 2016 Nov; 55(11):1435-1445. PubMed ID: 27225997
[TBL] [Abstract][Full Text] [Related]
6. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
[TBL] [Abstract][Full Text] [Related]
7. Accurate prediction of dose-dependent CYP3A4 inhibition by itraconazole and its metabolites from in vitro inhibition data.
Templeton I; Peng CC; Thummel KE; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2010 Oct; 88(4):499-505. PubMed ID: 20739919
[TBL] [Abstract][Full Text] [Related]
8. A mechanistic physiologically based pharmacokinetic-enzyme turnover model involving both intestine and liver to predict CYP3A induction-mediated drug-drug interactions.
Guo H; Liu C; Li J; Zhang M; Hu M; Xu P; Liu L; Liu X
J Pharm Sci; 2013 Aug; 102(8):2819-36. PubMed ID: 23760985
[TBL] [Abstract][Full Text] [Related]
9. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Yu Y; Loi CM; Hoffman J; Wang D
J Clin Pharmacol; 2017 Feb; 57(2):173-184. PubMed ID: 27402157
[TBL] [Abstract][Full Text] [Related]
10. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates.
Ramsden D; Fung C; Hariparsad N; Kenny JR; Mohutsky M; Parrott NJ; Robertson S; Tweedie DJ
Drug Metab Dispos; 2019 Oct; 47(10):1206-1221. PubMed ID: 31439574
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the Potential for Drug-Drug Interactions with Inhaled Itraconazole Using Physiologically Based Pharmacokinetic Modelling, Based on Phase 1 Clinical Data.
Bergagnini-Kolev M; Kane K; Templeton IE; Curran AK
AAPS J; 2023 Jun; 25(4):62. PubMed ID: 37344751
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
[TBL] [Abstract][Full Text] [Related]
13. PKPD and cardiac single cell modeling of a DDI study with a CYP3A4 substrate and itraconazole to quantify the effects on QT interval duration.
Jaminion F; Bentley D; Wang K; Wandel C; Derks M; Diack C
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):447-459. PubMed ID: 32572738
[TBL] [Abstract][Full Text] [Related]
14. Development, Verification, and Prediction of Osimertinib Drug-Drug Interactions Using PBPK Modeling Approach to Inform Drug Label.
Pilla Reddy V; Walker M; Sharma P; Ballard P; Vishwanathan K
CPT Pharmacometrics Syst Pharmacol; 2018 May; 7(5):321-330. PubMed ID: 29468841
[TBL] [Abstract][Full Text] [Related]
15. PBPK Models for CYP3A4 and P-gp DDI Prediction: A Modeling Network of Rifampicin, Itraconazole, Clarithromycin, Midazolam, Alfentanil, and Digoxin.
Hanke N; Frechen S; Moj D; Britz H; Eissing T; Wendl T; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2018 Oct; 7(10):647-659. PubMed ID: 30091221
[TBL] [Abstract][Full Text] [Related]
16. Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.
Templeton IE; Thummel KE; Kharasch ED; Kunze KL; Hoffer C; Nelson WL; Isoherranen N
Clin Pharmacol Ther; 2008 Jan; 83(1):77-85. PubMed ID: 17495874
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic modeling of the dosing interval dependency for the interaction between itraconazole and triazolam.
Toi A; Ohtani H; Tsujimoto M; Sawada Y
Int J Clin Pharmacol Ther; 2010 Jun; 48(6):356-66. PubMed ID: 20497744
[TBL] [Abstract][Full Text] [Related]
18. Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Biopharm Drug Dispos; 2019 May; 40(5-6):176-187. PubMed ID: 30985942
[TBL] [Abstract][Full Text] [Related]
19. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
Fenneteau F; Poulin P; Nekka F
J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
[TBL] [Abstract][Full Text] [Related]
20. Best practices for the use of itraconazole as a replacement for ketoconazole in drug-drug interaction studies.
Liu L; Bello A; Dresser MJ; Heald D; Komjathy SF; O'Mara E; Rogge M; Stoch SA; Robertson SM
J Clin Pharmacol; 2016 Feb; 56(2):143-51. PubMed ID: 26044116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
